¿Ü»ó¼º ³ú¼Õ»ó ÈÄ ¹ß»ýÇÑ ±¸°­ ¾È¸é ¿îµ¿À̻󿡼­ ¸ÞÅäŬ·ÎÇÁ¶ó¸¶À̵åÀÇ Åõ¿© ÈÄ È£Àü 1¿¹ - Áõ·Ê º¸°í -
Trial of Metoclopramide on Oro-facial Dyskinesia Following Traumatic Brain Injury - A Case Report -

Brain & NeuroRehabilitation 2014³â 7±Ç 2È£ p.147 ~ p.150

±è½Â±â(Kim Seung-Ki) - ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ÀçÈ°ÀÇÇб³½Ç
±èÁØ¿±(Kim Joon-Yeop) - ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ÀçÈ°ÀÇÇб³½Ç
±èÇü¼·(Kim Hyoung-Seop) - ±¹¹Î°Ç°­º¸Çè°ø´Ü Àϻ꺴¿ø ÀçÈ°ÀÇÇаú

Abstract

Oro-facial dyskinesia is characterized by involuntary repetitive movements of the tongue, lip, or jaw, which is known to be derived by variable causes. Pre- and post-synaptic dopamine receptor abnormalities by degenerative changes in the brain seem to be the key pathophysiology, but the exact mechanism still remained to be unknown. Metoclopramide can pass the blood-brain barrier, which is known for a selective presynaptic autoregulating dopamine D2 receptor antagonist in the brain, and is usually prescribed for dyspepsia, nausea and vomiting. In particular, it was also reported to improve the symptoms of diurnal bruxism after brain injury. With reviewing some of literatures, we present a case of 27 year old man with traumatic brain injury who showed improvement of oro-facial dyskinesia after taking oral metoclopramide.

Å°¿öµå

dopamine receptors, dyskinesias, metoclopramide
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå